CJC-1295 DAC Peptide in Vials

• Active ingredient: CJC-1295 with DAC
• Product name: CJC-1295 DAC 2 mg
• Manufacturer: Deus Medical
• Dosage form: Lyophilized powder in a vial
• Strength: 2 mg per vial
• Pharmacological class: GHRH analog / peptide

What is CJC-1295 DAC?

CJC-1295 DAC by Deus Medical contains 2 mg of CJC-1295 with Drug Affinity Complex per vial. The compound is a synthetic analog of growth hormone-releasing hormone (GHRH) and activates corresponding receptors in the pituitary gland, which can influence the body’s natural release of growth hormone.

The key difference compared with short-acting GHRH peptides is the DAC modification (Drug Affinity Complex). It enables CJC-1295 to bind to albumin and thereby significantly extends its availability in the body. Its half-life is approximately 6-8 days.

CJC-1295 DAC does not contain ready-made growth hormone. Instead, the peptide acts on the body’s own GH regulation and can increase both growth hormone and IGF-1 levels over a prolonged period. Human studies have observed sustained elevations in both parameters following administration of CJC-1295.

Because of this prolonged duration of action, the DAC version differs substantially from CJC-1295 without DAC and from short-acting variants such as Mod GRF 1-29.

CJC-1295 DAC in bodybuilding – uses and effects

In bodybuilding, CJC-1295 DAC is mainly of interest because of its prolonged stimulation of the body’s own GH/IGF-1 axis. Unlike short-acting peptides, the compound remains active for several days and is therefore associated with much longer intervals between administrations.

Typical goals associated with CJC-1295 DAC include:

• support for recovery and recuperation;
• promotion of an anabolic environment for building and preserving muscle mass;
• support for body composition during controlled gaining or cutting phases;
• prolonged stimulation of endogenous growth hormone release;
• elevated IGF-1 levels over an extended period;
• lower administration frequency than with short-acting GHRH peptides.

The main practical difference lies less in particularly rapid effects and more in prolonged and relatively steady activity. CJC-1295 DAC is therefore more commonly associated with longer-term use than with short-term effects.

Changes in muscle mass, fat metabolism, recovery or physical appearance continue to depend strongly on training, nutrition, sleep, starting condition and individual hormonal response. Scientific evidence for specific bodybuilding outcomes is considerably more limited than the evidence showing increases in GH and IGF-1.

How does CJC-1295 with DAC work?

CJC-1295 activates GHRH receptors in the pituitary gland and can thereby increase the body’s natural secretion of growth hormone. Growth hormone in turn influences the production of IGF-1, which is involved in various aspects of protein, fat and carbohydrate metabolism.

The DAC modification significantly extends the time the peptide remains active in the body. In a clinical study, GH remained elevated for at least six days after a single administration, while elevated IGF-1 levels were observed for an even longer period.

CJC-1295 with DAC and CJC-1295 without DAC should therefore not be treated as interchangeable versions. The DAC form has a considerably longer duration of action and is used accordingly.

In bodybuilding practice, CJC-1295 DAC is sometimes combined with a ghrelin mimetic such as Ipamorelin. The two peptides influence growth hormone regulation through different signaling pathways, which is why the combination is discussed in connection with stronger GH stimulation.

CJC-1295 DAC dosage and use

Each vial contains 2 mg of CJC-1295 with DAC as a lyophilized powder. The product must be properly reconstituted before use.

Because of its prolonged activity, non-medical bodybuilding protocols typically describe much longer intervals between administrations than with short-acting GHRH peptides.

Commonly reported practical parameters include:

• Typical range: approximately 1-2 mg per week;
• Administration frequency: often once or twice per week;
• Half-life: approximately 6-8 days;
• Route of administration: subcutaneous;
• Typical duration of use: approximately 12-16 weeks;
• Combination: sometimes used together with a ghrelin mimetic such as Ipamorelin.

The long half-life is the defining characteristic of CJC-1295 DAC. It allows the compound to remain active for a large part of the week, meaning that the multiple daily administrations associated with short-acting GHRH peptides are not required. The clinically determined half-life of CJC-1295 was approximately 5.8-8.1 days.

This prolonged activity is also the key difference compared with No-DAC variants: short-term changes in the amount used do not immediately alter the quantity of a long-acting peptide that is already circulating in the body.

Note: The ranges and usage patterns mentioned above describe practices reported in non-medical bodybuilding and do not constitute individualized medical dosing or usage advice.

What results are associated with CJC-1295 DAC?

CJC-1295 DAC is not associated with an immediate short-term effect in the way a stimulant would be. Instead, the emphasis is on sustained modulation of the GH/IGF-1 axis over a longer period.

Users commonly associate it with:

• improved recovery between training sessions;
• support for preserving lean muscle mass;
• promotion of a favorable environment for muscle development;
• support for body composition;
• improved recovery during intensive training periods;
• prolonged elevation of GH and IGF-1 activity.

Changes in sleep quality or overall feelings of recovery are also reported, but these effects are individual and considerably less well studied than the influence of CJC-1295 on GH and IGF-1 levels.

The extent to which changes in body composition become visible depends substantially on nutrition, training, calorie balance and individual response.

What should be considered with CJC-1295 DAC?

Because CJC-1295 DAC influences the growth hormone and IGF-1 axis, adverse effects may occur.

These may include:

• water retention and swelling;
• tingling or numbness in the hands and feet;
• headaches, muscle pain or joint discomfort;
• fatigue or dizziness;
• injection-site reactions;
• changes in glucose metabolism;
• undesirably high GH or IGF-1 levels.

Particular caution is warranted in people with existing disorders of glucose metabolism, hormonal conditions, or current or previous tumors.

Competitive athletes should also be aware that CJC-1295 is classified under WADA rules as a prohibited growth hormone-releasing factor.

The lyophilized product should be stored according to the manufacturer’s instructions and protected from light and excessive heat. After reconstitution, the applicable refrigeration and storage-duration instructions should be followed. Do not freeze.

Buy CJC-1295 DAC at Dinespower

CJC-1295 DAC is mainly sought by users who prefer prolonged influence on the body’s own GH/IGF-1 axis with longer intervals between administrations. With CJC-1295 DAC 2 mg by Deus Medical, Dinespower offers a lyophilized peptide containing 2 mg of active ingredient per vial.

Reliable active ingredient content, traceable product origin and appropriate storage conditions are particularly important for peptide products. Dinespower offers several advantages:

• Official distribution of selected brands and manufacturers;
• Laboratory analyses to verify the active ingredient and product quality;
• Product authenticity verification;
• Original products from established manufacturers such as Deus Medical;
• Secure and discreet delivery;
• Competitive prices;
• Current information on availability and shipping;
• Support with questions related to the product, ordering and delivery.

The current CJC-1295 DAC price and availability are shown directly on the product page. Customers who want to order CJC-1295 DAC online can find original products at Dinespower with traceable sourcing, transparent product information and available laboratory analyses.